The Understanding (tumour-host interactions) Cluster has published a joint press release summarising the main conclusions of its first annual meeting. The document highlights progress in collaborative research, data management, patient engagement and policy development, contributing to the objectives of the EU Cancer Mission.
Download the full press release on our materials page to learn more about the cluster’s priorities and planned actions.
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.
